Details for Patent: 5,194,443

Title:	Compounds
Abstract:	Compounds of formula (I): ##STR1## or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; R.sup.1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.
Inventor(s):	Hindley; Richard M. (Epsom, GB2)
Assignee:	Beecham Group p.l.c. (Brentford, GB2)
Filing Date:	Jan 24, 1991
Application Number:	07/645,092
Claims:	1. A compound of formula (I): ##STR93## or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted fused ring aromatic heterocyclyl groups wherein each ring comprises 4 to 7 ring atoms and each ring comprises 1, 2 or 3 hetero atoms selected from oxygen, sulphur or nitrogen and wherein the substituents for each ring include up to 4 substituents selected from the group consisting of: C.sub.1-12 -alkyl, C.sub.1-12 -alkoxy, phenyl or naphthyl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, form a benzene ring, and wherein the carbon atoms of the benzene ring represented by the said two substituents may themselves be substituted or unsubstituted optional substituents for the benzene ring being up to three groups selected from halogen, C.sub.1-12 alkyl, phenyl, C.sub.1-12 alkoxy, halo C.sub.1-12 alkyl, hydroxy, amino, nitro, carboxy, C.sub.1-12 alkoxycarbonyl, C.sub.1-12 alkoxycarbonyl C.sub.1-12 alkyl, C.sub.1-12 alkylcarbonyloxy and C.sub.1-12 alkylcarbonyl groups; R.sup.1 represents a hydrogen atom, a C.sub.1-12 alkyl group, a C.sub.1-12 alkyl carbonyl group, an aryl C.sub.1-12 alkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group, any aryl group being phenyl or naphthyl, optionally substituted with up to five groups selected from halogen, C.sub.1-12 alkyl, phenyl, C.sub.1-12 alkoxy, halo C.sub.1-12 alkyl, hydroxy, amino, nitro, carboxy, C.sub.1-12 alkoxycarbonyl, C.sub.1-12 alkoxycarbonyl C.sub.1-12 alkyl, C.sub.1-12 alkylcarbonyloxy and C.sub.1-12 alkylcarbonyl groups; R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond; A.sup.2 represents a benzene ring having three optional substituents which may be selected from halogen, substituted or unsubstituted C.sub.1-12 -alkyl or C.sub.1-12 -alkoxy, optional substituents for any alkyl group being up to five groups selected from halogen, C.sub.1-12 alkyl, phenyl, C.sub.1-12 alkoxy, halo C.sub.1-12 alkyl, hydroxy, amino, nitro, carboxy, C.sub.1-12 alkoxycarbonyl, C.sub.1-12 alkoxycarbonyl C.sub.1-12 alkyl, C.sub.1-12 alkylcarbonyloxy and C.sub.1-12 alkylcarbonyl groups; and n represents an integer in the range of from 2 to 6. 2. A pharmaceutical composition comprising a compound of formula (I) according to claim 1, or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor. 3. A method for the treatment and/or prophylaxis of hyperglycaemia in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of formula (I) according to claim 1, or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a hyperglycaemic human or non-human mammal in need thereof. 4. A method for the treatment of hyperlipidaemia in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I) according to claim 1, or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, to a hyperlipidaemic human or non-human mammal in need thereof.